Colleagues, the following is FYI and does not necessarily reflect my own
opinion. I have no further knowledge of the topic.
------------------------
J Clin Endocrinol Metab. 2005 May;90(5):2816-22. Epub 2005 Feb 22.
Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in
Postmenopausal Women with Osteoporosis: Treatment of Peripheral
Osteoporosis (TROPOS) Study.
Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J,
Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen
OH, Felsenberg D, Meunier PJ.
Department of Epidemiology, Public Health and Health Economics,
University of Liege, CHU Centre ville, 45 Quai Godefroid Kurth, 4020
Liege, Belgium. [log in to unmask]
Background: Strontium ranelate, a new oral drug shown to reduce
vertebral fracture risk in postmenopausal women with osteoporosis, was
studied in the Treatment of Peripheral Osteoporosis (TROPOS) study to
assess its efficacy and safety in preventing nonvertebral fractures
also. Methods: Strontium ranelate (2 g/d) or placebo were randomly
allocated to 5091 postmenopausal women with osteoporosis in a
double-blind placebo-controlled 5-yr study with a main statistical
analysis over 3 yr of treatment. Findings: In the entire sample,
relative risk (RR) was reduced by 16% for all nonvertebral fractures (P
= 0.04), and by 19% for major fragility fractures (hip, wrist, pelvis
and sacrum, ribs and sternum, clavicle, humerus) (P = 0.031) in
strontium ranelate-treated patients in comparison with the placebo
group. Among women at high risk of hip fracture (age >/=74 yr and
femoral neck bone mineral density T score </=-3, corresponding to -2.4
according to NHANES reference) (n = 1977), the RR reduction for hip
fracture was 36% (P = 0.046). RR of vertebral fractures was reduced by
39% (P < 0.001) in the 3640 patients with spinal x-rays and by 45% in
the subgroup without prevalent vertebral fracture. Strontium ranelate
increased bone mineral density throughout the study, reaching at 3 yr (P
< 0.001): +8.2% (femoral neck) and +9.8% (total hip). Incidence of
adverse events (AEs) was similar in both groups. Conclusion: This study
shows that strontium ranelate significantly reduces the risk of all
nonvertebral and in a high-risk subgroup, hip fractures over a 3-yr
period, and is well tolerated. It confirms that strontium ranelate
reduces vertebral fractures. Strontium ranelate offers a safe and
effective means of reducing the risk of fracture associated with
osteoporosis.
PMID: 15728210 [PubMed - in process]
--
Kathrynne Holden, MS, RD < [log in to unmask] >
"Ask the Parkinson Dietitian" http://www.parkinson.org/
"Eat well, stay well with Parkinson's disease"
"Parkinson's disease: Guidelines for Medical Nutrition Therapy"
http://www.nutritionucanlivewith.com/
----------------------------------------------------------------
This message was sent through the Ageing in Europe
mailing list.
Please visit the homepage of the ESA Research Network
on Ageing in Europe at http://www.ageing-in-europe.de
----------------------------------------------------------------
|